GlobeNewsWire · CLLS · October 27, 2026

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

Get the app for more

Explore stock news, insights and company research.